

Supplemental information

**Characterization of a novel OX40 ligand
and CD40 ligand-expressing oncolytic adenovirus
used in the PeptiCRAd cancer vaccine platform**

Erkko Ylösmäki, Leena Ylösmäki, Manlio Fucciello, Beatriz Martins, Petra Ahokas, Hanne Cojoc, Arttu Uoti, Sara Feola, Anna Kreutzman, Tuuli Ranki, Julia Karbach, Tapani Viitala, Petri Priha, Elke Jäger, Sari Pesonen, and Vincenzo Cerullo

Supplemental Information

Fig. S1. Individual tumour growth curves of oncolytic potency of VALO-D102 presented in Figure 3 panel F.




Fig. S2. Individual tumour growth curves for the experiment presented in Figure 4.




Fig. S3. Individual tumour growth curves for the experiment presented in Figure 5.




Fig. S4. Individual tumour growth curves for the experiment presented in Figure 6.




Fig. S5. Alignment of sequence analysis from directly after plaque purification and after seven rounds of amplification.